Yang Xiang to Patient Reported Outcome Measures
This is a "connection" page, showing publications Yang Xiang has written about Patient Reported Outcome Measures.
Connection Strength
0.263
-
Du M, Peng P, Cao D, Cheng N, Yao L, Sun Y, Li J, Zhang H, Lou G, Tang J, Wang D, Wang Y, Zhang G, Xiang Y. Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study. J Ovarian Res. 2026 Jan 26; 19(1).
Score: 0.212
-
Randall L, Xiang Y, Matsumoto T, Giannarelli D, Milla DP, Lopez KA, Acevedo A, Vizkeleti J, Salani R, Nogueira-Rodrigues A, Mejia FC, Korach J, Akilli H, Lee JY, Saevets VV, Samouelian V, Sehouli J, Tharavichikul E, Sukhin V, Colombo N, Chang CL, Cueva JF, Lalondrelle S, Petru E, Szamreta E, Nguyen AM, Yamada K, Li K, Pignata S, Lorusso D. Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecol Oncol. 2025 08; 199:88-95.
Score: 0.051